I-BET151 (GSK1210151A)
- ₹15403.98 - ₹62633.45
- Product name: I-BET151 (GSK1210151A)
- CAS: 1300031-49-5
- MF: C23H21N5O3
- MW: 415.44
- EINECS:
- MDL Number:MFCD22124472
- Synonyms:7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one;I-BET 151/GSK 1210151A;GSK1210151A (I-BET151);7-(3,5-diMethylisoxazol-4-yl)-8-Methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-iMidazo[4,5-c]quinolin-2(3H)-one;7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2;GSK 1210151A;I-BET 151;7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one I-BET151(GSK1210151A)
2 prices
Selected condition:
Brand
- Sigma-Aldrich(India)
Package
- 5MG
- 25MG
- ManufacturerSigma-Aldrich(India)
- Product numberSML0666
- Product descriptionGSK1210151A ≥98% (HPLC)
- Packaging5MG
- Price₹15403.98
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberSML0666
- Product descriptionGSK1210151A ≥98% (HPLC)
- Packaging25MG
- Price₹62633.45
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich(India) | SML0666 | GSK1210151A ≥98% (HPLC) | 5MG | ₹15403.98 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | SML0666 | GSK1210151A ≥98% (HPLC) | 25MG | ₹62633.45 | 2022-06-14 | Buy |
Properties
Density :1.314
storage temp. :2-8°C
solubility :DMSO: soluble20mg/mL, clear
form :powder
pka :11.14±0.20(Predicted)
color :white to beige
storage temp. :2-8°C
solubility :DMSO: soluble20mg/mL, clear
form :powder
pka :11.14±0.20(Predicted)
color :white to beige
Safety Information
Symbol(GHS): | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||
Hazard statements: |
|
||||||||||||||
Precautionary statements: |
|
Description
The bromodomain and extra terminal domain (BET) family of proteins including BRD2, BRD3, and BRD4 play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interaction by controlling the assembly of histone acetylation-dependent chromatin complexes. I-BET151 is an isoxazole class pan-BET family inhibitor, blocking BRD2, BRD3, and BRD4 with IC50 values of 0.5, 0.25, and 0.79 μM, respectively. Through this action, it blocks the growth of leukemic cell lines driven by mixed lineage leukemia (MLL) fusions at nanomolar concentrations, whereas tyrosine kinase activated cells were much less sensitive. Specifically, I-BET151 induces apoptosis via reduced expression of BCL2 or triggers G0/G1 cell cycle arrest in MLL-fusion cell lines. I-BET151 is effective in vivo, suppressing MLL leukemia progression in two different mouse models.Related product price
- (1S,4Z,7S,10S,11E,20R)-4-ethylidene-7,20-dipropan-2-yl-9-oxa-15,16-dit hia-3,6,18,21-tetrazabicyclo[8.7.6]tricos-11-ene-2,5,8,19,22-pentone
₹31652.3 - OTX015
₹8400-96591.48 - CPI-203
₹14916.85-60024.63